According to the Zhitong Finance App, Gacos-B (01167) announced the results for the year ended December 31, 2023. The group recorded revenue of 63.52 million yuan, and the loss due to company owners during the year decreased by 3.4% year-on-year.

According to the report, revenue was due to reimbursement of R&D costs resulting from licensing and cooperation agreements signed with AbbVie to develop, manufacture and commercialize SHP2 inhibitors.